Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2005
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Tissue-Selective Nuclear Receptors (D4)
Organizer(s) William T. Schrader, John A. Cidlowski, Kenneth S. Korach and Donald P. McDonnell
September 18—22, 2005
Beaver Run Resort • Breckenridge, CO USA
Abstract Deadline: Jun 17, 2005
Late Abstract Deadline: Jul 1, 2005
Scholarship Deadline: Jun 17, 2005
Early Registration Deadline: Jul 18, 2005
Sponsored by the Director's Fund
Summary of Meeting:
The nuclear hormone receptors engender great research interest, and have spawned numerous scientific meetings. The past Keystone Symposia dealt with this topic from the perspective of molecular biology. This meeting will bring together three aspects of research impacting human health via the nuclear receptors. These three groups are (a) basic scientists, (b) pharmaceutical drug discoverers and (c) clinicians. The meeting will unfold a series of questions regarding unmet medical needs for drugs involving nuclear receptor ligands, recent advances towards a molecular understanding of tissue-selectivity as a hallmark for improved safety and efficacy, and a resources workshop to address and fulfill needs for emerging novel research tools. This meeting will differ from other Keystone meetings dealing with the nuclear hormone receptor family by concentrating upon the link of molecular tools to unmet medical needs for improved therapeutics.
View Scholarships/Awards
The nuclear hormone receptors engender great research interest, and have spawned numerous scientific meetings. The past Keystone Symposia dealt with this topic from the perspective of molecular biology. This meeting will bring together three aspects of research impacting human health via the nuclear receptors. These three groups are (a) basic scientists, (b) pharmaceutical drug discoverers and (c) clinicians. The meeting will unfold a series of questions regarding unmet medical needs for drugs involving nuclear receptor ligands, recent advances towards a molecular understanding of tissue-selectivity as a hallmark for improved safety and efficacy, and a resources workshop to address and fulfill needs for emerging novel research tools. This meeting will differ from other Keystone meetings dealing with the nuclear hormone receptor family by concentrating upon the link of molecular tools to unmet medical needs for improved therapeutics.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, SEPTEMBER 18
MONDAY, SEPTEMBER 19
TUESDAY, SEPTEMBER 20
WEDNESDAY, SEPTEMBER 21
THURSDAY, SEPTEMBER 22
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, SEPTEMBER 18
19:30—21:30
Keynote Session: What's Wrong with Current NHR Therapies?
William T. Schrader,
NIEHS, National Institutes of Health, USA
Tissue-Selective Receptor Modulators: What Do We Know and What We Only Think We Know?
Tissue-Selective Receptor Modulators: What Do We Know and What We Only Think We Know?
J. Larry Jameson,
Northwestern University School of Medicine, USA
Unmet Medical Needs of NHR Therapies
Unmet Medical Needs of NHR Therapies
08:00—11:00
Human Disease Targets for Tissue-Selective Modulators
*
William T. Schrader,
NIEHS, National Institutes of Health, USA
William W. Chin,
Harvard Medical School, USA
Selective NRH as Novel Therapeutics
Selective NRH as Novel Therapeutics
John D. Baxter,
University of California, San Francisco, USA
Selective Modulation of the Thyroid Hormone Receptor
Selective Modulation of the Thyroid Hormone Receptor
Gerald H. Nabozny,
Boehringer Ingelheim Inc., USA
Glucocorticoids and Inflammatory Disease
Glucocorticoids and Inflammatory Disease
Heather A. Harris,
Wyeth Pharmaceuticals, USA
Characterization and Potential Clinical Applications for Estrogen Receptor-beta Selective Agonists
Characterization and Potential Clinical Applications for Estrogen Receptor-beta Selective Agonists
17:00—19:00
Experimental Pharmacophores for Investigational Use
*
Richard Hochberg,
Yale University School of Medicine, USA
John A. Katzenellenbogen,
University of Illinois at Urbana-Champaign, USA
Critical Structural Features Underlying the Activities of Nuclear Hormone Receptor Ligands
Critical Structural Features Underlying the Activities of Nuclear Hormone Receptor Ligands
Lawrence G. Hamann,
Novartis Institutes for BioMedical Research, USA
Tissue Selective Androgen Receptor Modulators
Tissue Selective Androgen Receptor Modulators
Richard A. Heyman,
ORIC Pharmaceuticals, USA
The Intersection of Nuclear Receptors and Metabolic Syndrome
The Intersection of Nuclear Receptors and Metabolic Syndrome
08:00—11:00
Mouse Genetic Models
Günther Schütz,
German Cancer Research Center, Germany
Analysis of Glucocorticoid-, Mineralocorticoid- and Estrogen-Receptor Function by Gene Targeting
Analysis of Glucocorticoid-, Mineralocorticoid- and Estrogen-Receptor Function by Gene Targeting
Adriana Maggi,
University of Milan, Italy
A Mouse Reporting on ER Transcriptional Activity to Understand the Complexities of Female Physiology in Mammals
A Mouse Reporting on ER Transcriptional Activity to Understand the Complexities of Female Physiology in Mammals
*
Kenneth S. Korach,
NIEHS, National Institutes of Health, USA
Estrogen Receptor Pharmacology in Mouse Lines
Estrogen Receptor Pharmacology in Mouse Lines
David J. Mangelsdorf,
University of Texas Southwestern Medical Center, USA
The Role of LXRs and FXR in Enterohepatic Lipid Metabolism
The Role of LXRs and FXR in Enterohepatic Lipid Metabolism
17:00—19:00
Tissue-Selective Receptor Expression and Function
Keith R. Yamamoto,
University of California, San Francisco, USA
Physiological Expression Patterns Reflect Integration of “Sectors” of Multiple Regulatory Networks
Physiological Expression Patterns Reflect Integration of “Sectors” of Multiple Regulatory Networks
John A. Cidlowski,
NIEHS, National Institutes of Health, USA
The Glucocorticoid Receptor: One Gene, Many Proteins, Extensive Post Translational Modifications
The Glucocorticoid Receptor: One Gene, Many Proteins, Extensive Post Translational Modifications
Richard C. Winneker,
Wyeth Pharmaceuticals, USA
Tissue Selective Properties of a Novel, Nonsteroidal Progesterone Receptor Agonist, Tanaproget
Tissue Selective Properties of a Novel, Nonsteroidal Progesterone Receptor Agonist, Tanaproget
08:00—11:00
Coactivator and Corepressor Proteins and the Tissue Selectivity Problem
*
William T. Schrader,
NIEHS, National Institutes of Health, USA
Jeffrey N. Miner,
Ligand Pharmaceuticals, USA
Steroid Receptor Modulators: Approaches to Selectivity for Androgen Receptor
Steroid Receptor Modulators: Approaches to Selectivity for Androgen Receptor
Bert W. O'Malley,
Baylor College of Medicine, USA
Coactivators and Tissue Specific Responses to Nuclear Receptors
Coactivators and Tissue Specific Responses to Nuclear Receptors
Donald P. McDonnell,
Duke University School of Medicine, USA
The Biological Consequences of Differential Nuclear Receptor-Cofactor Interactions
The Biological Consequences of Differential Nuclear Receptor-Cofactor Interactions
14:30—16:30
Workshop
*
Donald P. McDonnell,
Duke University School of Medicine, USA
Anne Minnich,
Sanofi Phamaceuticals, USA
Effects of Potent and Bioavailable PPARalpha and gamma Agonists in Inflammatory Disease Models
Effects of Potent and Bioavailable PPARalpha and gamma Agonists in Inflammatory Disease Models
Thomas A. Gustafson,
Johnson and Johnson, USA
Metaglidasen (MBX-102), a Non-TZD Selective PPARgamma Modulator (SPPARgammaM) with Potent Anti-Diabetic and Hypo-Lipidemic Activity in the Absence of Significant Body or Heart Weight Increases
Metaglidasen (MBX-102), a Non-TZD Selective PPARgamma Modulator (SPPARgammaM) with Potent Anti-Diabetic and Hypo-Lipidemic Activity in the Absence of Significant Body or Heart Weight Increases
Christine Y. Ivashchenko,
Sigilon Therapeutics, USA
Knockout of PPARgamma in Endothelial Cells Increases the Inflammatory Response to TNF-alpha
Knockout of PPARgamma in Endothelial Cells Increases the Inflammatory Response to TNF-alpha
Jun Xia,
University of Illinois at Urbana-Champaign, USA
Structural Determinants of Constitutive Androstane Receptor (CAR) Required for its Glucocorticoid Receptor Interacting Protein-1 (GRIP1)- Mediated Nuclear Accumulation
Structural Determinants of Constitutive Androstane Receptor (CAR) Required for its Glucocorticoid Receptor Interacting Protein-1 (GRIP1)- Mediated Nuclear Accumulation
Wen Xie,
University of Pittsburgh, USA
Pathway- and Gender-Specific Cross-Talk between Xenobiotic Receptors PXR and CAR
Pathway- and Gender-Specific Cross-Talk between Xenobiotic Receptors PXR and CAR
Edwin R. Sanchez,
University of Toledo College of Medicine, USA
Selective Targeting of Steroid-Regulated Physiologies via TPR Co-Chaperones
Selective Targeting of Steroid-Regulated Physiologies via TPR Co-Chaperones
Emily J. Faivre,
AbbVie, Inc., USA
Liganded Human Progesterone Receptor Induces Src-Dependent Oscillations of Erk 1/2 MAPK Activity via Transactivation of the EGFR in a Breast Cancer Cell Model
Liganded Human Progesterone Receptor Induces Src-Dependent Oscillations of Erk 1/2 MAPK Activity via Transactivation of the EGFR in a Breast Cancer Cell Model
Jacek Ostrowski,
Bristol-Myers Squibb Company, USA
Chromatin Acetylation is a Potential Mechanism for the Differential Effects of Novel Non-Steroidal Ligands on Transactivation Activity of Androgen Receptor in Mouse Myoblast C2C12 Cells
Chromatin Acetylation is a Potential Mechanism for the Differential Effects of Novel Non-Steroidal Ligands on Transactivation Activity of Androgen Receptor in Mouse Myoblast C2C12 Cells
17:00—19:00
Receptor Structure and Imaging
Timothy M. Willson,
GlaxoSmithKline, USA
Characterization of PPAR Modulators Derived from Structure-Guided Synthesis
Characterization of PPAR Modulators Derived from Structure-Guided Synthesis
Dino Moras,
Institute of Genetics, Molecular and Cellular Biology, France
Structural basis for ligand (in) dependent activity of RXR
Structural basis for ligand (in) dependent activity of RXR
Donald B. Defranco,
University of Pittsburgh School of Medicine, USA
Role of Molecular Chaperones in Nuclear Mobility and Hormone Exchange of Glucocorticoid Receptors
Role of Molecular Chaperones in Nuclear Mobility and Hormone Exchange of Glucocorticoid Receptors
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
